
Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. Patients being treated with dabigatran therapy have underlying disease states that predispose them to thromboembolic events. 5 WARNINGS AND PRECAUTIONS Thromboembolic Risk Injection: 2.5 g/50 mL solution in a single-dose vial. Praxbind is a sterile, preservative-free, colorless to slightly yellow, clear to slightly opalescent solution available as: Related/similar drugs idarucizumab 3 DOSAGE FORMS AND STRENGTHS

The solution in vials may be stored at room temperature, 25☌ (77☏), but must be used within 6 hours. Once solution has been removed from the vial, administration should begin promptly.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.Ensure aseptic handling when preparing the infusion.Remove both vials (each containing 2.5 g/50 mL idarucizumab) from carton.There is limited data to support administration of an additional 5 g of Praxbind. Both vials are packaged together in one carton.

The recommended dose of Praxbind is 5 g, provided as two separate vials each containing 2.5 g/50 mL idarucizumab (see Figure 1).
